In addition to our ongoing work on G-quadruplexes, we are actively pursuing a variety of synthetic strategies aimed at expanding our toolkit for medicinal chemistry and chemical biology. For example, we engage in the total synthesis of bioactive molecules, which enables a deeper understanding of their mechanism of action. We are also investigating peptides and peptidomimetics, leveraging rational design to optimize their immunogenic potential., and many other projects

SPLICING MODULATORS

The spliceosome (SPL) encompasses a broad array of complexes made up of small nuclear RNAs and proteins, forming a sophisticated machinery in eukaryotic cells. When splicing factors (mRNA segments for protein removal) undergo somatic mutations, the binding/recognition of NC sequences may become defective, leading to the selection of a cryptic (incorrect) splice site (SS) and resulting in aberrant transcripts. This aberrant splicing induced by mutations in splicing factors has been identified as a key pathway in cancer onset. Small molecules that specifically target components of the SPL offer intriguing prospects for developing candidate drugs against cancer, given the deregulation of splicing. To this end, we are focusing our efforts on two main approaches. The first involves the total synthesis of novel herboxidiene derivatives capable of selectively binding our target and acting as splicing modulators. The second approach entails the synthesis of stable, cyclic peptides, as computational analysis has suggested that the allosteric binding pocket may also be recognized by specific peptides.

peptides for epitopal vaccines

In the framework of ImmunoHub, a collaborative initiative uniting multiple research institutions across Italy, we focus on developing peptide-based epitopal vaccines targeting SARS-CoV-2 and Mycobacterium tuberculosis. Both manual peptide synthesis and an automated solid-phase peptide synthesis (SPPS) system are employed, significantly reducing synthetic efforts and accelerating the production of candidate epitopes. Through computational design and rational screening, immunodominant sequences are identified for their ability to elicit strong and protective immune responses. Close collaboration with immunologists ensures that vaccine candidates meet high standards of efficacy and safety, ultimately contributing to innovative, accessible solutions for critical global health challenges.

collagen hybridizing peptides and molecular treatment of osteogenesis imperfecta

Focusing on molecular strategies to address osteogenesis imperfecta—a rare genetic disorder marked by brittle bones—this group develops collagen-hybridizing peptides that selectively bind compromised collagen in skeletal tissue. Through careful sequence design and synthesis, including both manual methods and automated platforms, candidate peptides are refined to maximize their ability to stabilize damaged collagen triple helices. Collaborative efforts with clinical researchers enable in vitro and in vivo assessments of peptide safety and efficacy, laying the foundation for potential translational applications. This integrative approach aims to deliver innovative molecular treatments that can strengthen bone integrity and improve quality of life for individuals affected by osteogenesis imperfecta.